Based on the evidence,in 2014, Dao et al. designed a novel series of imidazo[1,2-a][1,3,5]triazine derivatives via structural modificationof the previously reported potent FAK inhibitory compound 18(PHM16), which showed striking anti-tumor activity (Figure 7). Here, PTK2 is linked to neoplasm.